top of page
  • Writer's pictureFutureMeds

FutureMeds’ Clinical Research Model Can Save Millions Daily & Accelerate Access to Treatments

Updated: Jan 24, 2023

FutureMeds’ Dedicated Research Site model, patient-centric approach, and effective recruitment strategies can mitigate trial delays, save millions of dollars daily and accelerate patients’ access to new treatments.

An estimated 85% of all clinical trials face delays, costing between $600,000 - $8 million daily, wasting precious time and burning patient confidence.

Once a trial is underway, the most common reason for the delay is the complex and challenging patient recruitment and retention; patients failing pre-screening, declining consent and dropping out after enrollment.

Trial delays may place an unwanted time burden on participants, leading them to exit trials, further compounding delays and problems. In addition, clinical trial delays potentially affect patient outcomes due to hindered commercialisation and delayed access to new treatments.

Our experienced team at FutureMeds found that although delays in clinical trials are common, they can be addressed and mitigated.

A Dedicated Research Site focus combined with DCT methodologies may provide winning advantages in easing patient recruitment challenges and increasing the flexibility of trial conduct.

Recent enrolment figures show that the FutureMeds model accelerates patient recruitment and, as a result, mitigates study delays.

For example, as a result of the FutureMeds formula and the outstanding work of our teams, 2 FutureMeds Dedicated Research Sites delivered around 7.5% of the target study population within ten weeks and became the top recruiter in the region for an ongoing Lyme disease study.

Another proof of our approach is related to an ongoing denosumab biosimilar Osteoporosis study. FutureMeds Dedicated Research Sites in Krakow and Warsaw have been featured as the top 2 Polish recruiters by the sponsor. Our Dedicated Research Sites enrolled 74 participants and outperformed countries; the second-best performing country randomised 52 participants, and the third enrolled 47 participants.

About FutureMeds

FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.

FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.

Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


Os comentários foram desativados.
bottom of page